Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.12
PTX's Cash to Debt is ranked lower than
53% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. PTX: 0.12 )
PTX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.12

Equity to Asset 0.17
PTX's Equity to Asset is ranked lower than
52% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. PTX: 0.17 )
PTX' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.77
Current: 0.17

0.14
0.77
F-Score: 5
Z-Score: 0.49
M-Score: -2.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -24.82
PTX's Operating margin (%) is ranked higher than
53% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. PTX: -24.82 )
PTX' s 10-Year Operating margin (%) Range
Min: -64.4   Max: 38.22
Current: -24.82

-64.4
38.22
Net-margin (%) -28.98
PTX's Net-margin (%) is ranked higher than
54% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. PTX: -28.98 )
PTX' s 10-Year Net-margin (%) Range
Min: -91.07   Max: 33.08
Current: -28.98

-91.07
33.08
ROE (%) -36.51
PTX's ROE (%) is ranked higher than
54% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. PTX: -36.51 )
PTX' s 10-Year ROE (%) Range
Min: -42.27   Max: 137.29
Current: -36.51

-42.27
137.29
ROA (%) -10.38
PTX's ROA (%) is ranked higher than
57% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. PTX: -10.38 )
PTX' s 10-Year ROA (%) Range
Min: -12.35   Max: 68.03
Current: -10.38

-12.35
68.03
ROC (Joel Greenblatt) (%) -241.95
PTX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. PTX: -241.95 )
PTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -291.56   Max: 1552.82
Current: -241.95

-291.56
1552.82
Revenue Growth (3Y)(%) 9.00
PTX's Revenue Growth (3Y)(%) is ranked higher than
88% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. PTX: 9.00 )
PTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 107
Current: 9

0
107
EBITDA Growth (3Y)(%) -51.90
PTX's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. PTX: -51.90 )
PTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 132.7
Current: -51.9

0
132.7
» PTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

PTX Guru Trades in Q2 2013

Jim Simons Sold Out
» More
Q2 2014

PTX Guru Trades in Q2 2014

Jim Simons 157,637 sh (New)
» More
Q3 2014

PTX Guru Trades in Q3 2014

Jim Simons 100,837 sh (-36.03%)
» More
Q4 2014

PTX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 8.98
PTX's Forward P/E is ranked higher than
99% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. PTX: 8.98 )
N/A
P/B 5.30
PTX's P/B is ranked higher than
66% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. PTX: 5.30 )
PTX' s 10-Year P/B Range
Min: 0.26   Max: 14.61
Current: 5.3

0.26
14.61
P/S 3.70
PTX's P/S is ranked higher than
71% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. PTX: 3.70 )
PTX' s 10-Year P/S Range
Min: 0.07   Max: 8.78
Current: 3.7

0.07
8.78
PFCF 64.90
PTX's PFCF is ranked higher than
61% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PTX: 64.90 )
PTX' s 10-Year PFCF Range
Min: 11.44   Max: 282.5
Current: 64.9

11.44
282.5
POCF 50.00
PTX's POCF is ranked higher than
56% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. PTX: 50.00 )
PTX' s 10-Year POCF Range
Min: 7.12   Max: 58.16
Current: 50

7.12
58.16
EV-to-EBIT -22.10
PTX's EV-to-EBIT is ranked lower than
54% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. PTX: -22.10 )
PTX' s 10-Year EV-to-EBIT Range
Min: -163.1   Max: 280.5
Current: -22.1

-163.1
280.5
Current Ratio 1.32
PTX's Current Ratio is ranked higher than
54% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. PTX: 1.32 )
PTX' s 10-Year Current Ratio Range
Min: 0.09   Max: 2.16
Current: 1.32

0.09
2.16
Quick Ratio 1.21
PTX's Quick Ratio is ranked higher than
59% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. PTX: 1.21 )
PTX' s 10-Year Quick Ratio Range
Min: 0.07   Max: 1.96
Current: 1.21

0.07
1.96
Days Inventory 97.23
PTX's Days Inventory is ranked higher than
80% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. PTX: 97.23 )
PTX' s 10-Year Days Inventory Range
Min: 36.32   Max: 220.74
Current: 97.23

36.32
220.74
Days Sales Outstanding 124.25
PTX's Days Sales Outstanding is ranked higher than
60% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. PTX: 124.25 )
PTX' s 10-Year Days Sales Outstanding Range
Min: 11.14   Max: 208.1
Current: 124.25

11.14
208.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 5.56
PTX's Price/DCF (Projected) is ranked higher than
74% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. PTX: 5.56 )
PTX' s 10-Year Price/DCF (Projected) Range
Min: 0.47   Max: 9.45
Current: 5.56

0.47
9.45
Price/Median PS Value 1.63
PTX's Price/Median PS Value is ranked higher than
60% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. PTX: 1.63 )
PTX' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 3.37
Current: 1.63

0.1
3.37
Earnings Yield (Greenblatt) -4.40
PTX's Earnings Yield (Greenblatt) is ranked higher than
54% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. PTX: -4.40 )
PTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 16.7
Current: -4.4

0.4
16.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:GTAP.Germany,
Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumberland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.
» More Articles for PTX

Headlines

Articles On GuruFocus.com
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Medical Stocks Highlight The Day's New Highs Mar 05 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-K, Annual Report Mar 02 2015
Pernix Therapeutics Inc. to Present at the Cowen and Company Health Care Conference in Boston, MA Mar 02 2015
Nationwide Wake-Up Call: New Survey Reveals More than Half of Americans Are Unable to Sleep... Mar 02 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Feb 27 2015
Pernix Therapeutics reports 4Q loss Feb 25 2015
Pernix Therapeutics Reports Fourth Quarter and 2014 Financial Results and Business Update Feb 25 2015
Q4 2014 Pernix Therapeutics Holdings Inc Earnings Release - Time Not Supplied Feb 25 2015
Pernix Therapeutics (PTX) Stock Gaining Today After Cantor Fitzgerald Initiates Coverage Feb 10 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Financial Statements and Exhibits Jan 30 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and... Jan 27 2015
CORRECTING and REPLACING Pernix Therapeutics Exceeds 2014 Revenue Guidance: Delivers FY2014 Net... Jan 20 2015
Pernix Therapeutics Announces FDA Acceptance With Priority Review of Its TREXIMET® sNDA for Use in... Jan 15 2015
Pernix Therapeutics Inc. to Present at the Oppenheimer Healthcare Conference in New York, NY Dec 01 2014
Pernix Therapeutics Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Financials Nov 22 2014
Pernix Submits sNDA for TREXIMET® Use in Adolescent Patients Nov 17 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial... Nov 10 2014
Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance Nov 10 2014
Pernix Therapeutics to Report Q3 2014 Financial Results Oct 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK